Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
Introduction: The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy. Aim: To perform a comparative assessment of the Sokal, Euro and EUT...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2018-01-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=258;epage=262;aulast=Chhikara |
| _version_ | 1818391277213843456 |
|---|---|
| author | Sunita Chhikara Sudha Sazawal Kanwaljeet Singh Rekha Chaubey Haraprasad Pati Seema Tyagi Manoranjan Mahapatra Renu Saxena |
| author_facet | Sunita Chhikara Sudha Sazawal Kanwaljeet Singh Rekha Chaubey Haraprasad Pati Seema Tyagi Manoranjan Mahapatra Renu Saxena |
| author_sort | Sunita Chhikara |
| collection | DOAJ |
| description | Introduction: The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy. Aim: To perform a comparative assessment of the Sokal, Euro and EUTOS prognostic score in Indian CML-CP patients on imatinib. Methods: This is a retrospective study performed in 260 Ph+ CML-CP patients who were administered oral imatinib (400 mg/day). Results: 166/260 were males and 94/260 were females (M: F::1.6:1) with median age 35 years (range 20-70). 92 (35.38%), 125 (48.07%) and 43 (16.5%) patients were divided into low, intermediate and high risk Sokal score respectively. 102 (39.23%), 106 (40.76%) and 52 (20%) patients were discriminated into low, intermediate and high risk Euro score respectively. 210 (80.7%) and 50 (19.2%) patients were divided into low and high risk EUTOS score. Cumulative incidence of MMR for low, intermediate and high-risk Sokal score was 87%, 76% and 84% respectively (P = 0.016). Incidence of MMR in low, intermediate and high-risk Euro score was 93%, 85% and 68% respectively (P = 0.001). Incidence of MMR was 80 % and 81% for low and high risk EUTOS score (P = 0.764). Both EFS and OS are significantly correlated with Sokal score (P = 0.004, P = 0.007) and Euro score (P = 0.009, P = 0.001) but not with EUTOS score (P = 0.581, P = 0.927). Conclusion: The present study highlights the significant prognostic role of Sokal and Euro score in predicting the treatment outcome of the CML- CP patients on imatinib. |
| first_indexed | 2024-12-14T05:10:58Z |
| format | Article |
| id | doaj.art-0bf4c89594b34d889224ab27579f9153 |
| institution | Directory Open Access Journal |
| issn | 2278-330X |
| language | English |
| last_indexed | 2024-12-14T05:10:58Z |
| publishDate | 2018-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj.art-0bf4c89594b34d889224ab27579f91532022-12-21T23:15:58ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2018-01-017425826210.4103/sajc.sajc_244_17Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinibSunita ChhikaraSudha SazawalKanwaljeet SinghRekha ChaubeyHaraprasad PatiSeema TyagiManoranjan MahapatraRenu SaxenaIntroduction: The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy. Aim: To perform a comparative assessment of the Sokal, Euro and EUTOS prognostic score in Indian CML-CP patients on imatinib. Methods: This is a retrospective study performed in 260 Ph+ CML-CP patients who were administered oral imatinib (400 mg/day). Results: 166/260 were males and 94/260 were females (M: F::1.6:1) with median age 35 years (range 20-70). 92 (35.38%), 125 (48.07%) and 43 (16.5%) patients were divided into low, intermediate and high risk Sokal score respectively. 102 (39.23%), 106 (40.76%) and 52 (20%) patients were discriminated into low, intermediate and high risk Euro score respectively. 210 (80.7%) and 50 (19.2%) patients were divided into low and high risk EUTOS score. Cumulative incidence of MMR for low, intermediate and high-risk Sokal score was 87%, 76% and 84% respectively (P = 0.016). Incidence of MMR in low, intermediate and high-risk Euro score was 93%, 85% and 68% respectively (P = 0.001). Incidence of MMR was 80 % and 81% for low and high risk EUTOS score (P = 0.764). Both EFS and OS are significantly correlated with Sokal score (P = 0.004, P = 0.007) and Euro score (P = 0.009, P = 0.001) but not with EUTOS score (P = 0.581, P = 0.927). Conclusion: The present study highlights the significant prognostic role of Sokal and Euro score in predicting the treatment outcome of the CML- CP patients on imatinib.http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=258;epage=262;aulast=ChhikaraChronic myeloid leukemia-chronic phaseEuroEuropean Treatment and Outcome StudyimatinibprognosticationSokal |
| spellingShingle | Sunita Chhikara Sudha Sazawal Kanwaljeet Singh Rekha Chaubey Haraprasad Pati Seema Tyagi Manoranjan Mahapatra Renu Saxena Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib South Asian Journal of Cancer Chronic myeloid leukemia-chronic phase Euro European Treatment and Outcome Study imatinib prognostication Sokal |
| title | Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib |
| title_full | Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib |
| title_fullStr | Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib |
| title_full_unstemmed | Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib |
| title_short | Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib |
| title_sort | comparative analysis of the sokal euro and european treatment and outcome study score in prognostication of indian chronic myeloid leukemia chronic phase patients on imatinib |
| topic | Chronic myeloid leukemia-chronic phase Euro European Treatment and Outcome Study imatinib prognostication Sokal |
| url | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=258;epage=262;aulast=Chhikara |
| work_keys_str_mv | AT sunitachhikara comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT sudhasazawal comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT kanwaljeetsingh comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT rekhachaubey comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT haraprasadpati comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT seematyagi comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT manoranjanmahapatra comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib AT renusaxena comparativeanalysisofthesokaleuroandeuropeantreatmentandoutcomestudyscoreinprognosticationofindianchronicmyeloidleukemiachronicphasepatientsonimatinib |